Chengdu Olymvax Biopharmaceuticals Inc(688319) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

688319 Chengdu Olymvax Biopharmaceuticals Inc

Watchlist

14.95
+0.51+3.53%

Market Closed Mar 31 15:00 CST

6.07BMarket Cap293.14P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Olin Bio (688319.SH): Net income for 2024 is approximately 20.76 million yuan, an increase of 18.24% year-on-year.
Gelonghui, March 29丨Olin Bio (688319.SH) announced that the revenue for 2024 is approximately 0.589 billion yuan, an increase of 18.69% year-on-year; the net income attributable to shareholders of the listed company is approximately 20.76 million yuan, an increase of 18.24% year-on-year; basic EPS is 0.0512 yuan.
Gelonghui FinanceMar 28 12:06 ET
Chengdu Olin Biotechnology Co., Ltd. 2024 Annual Report
SZSIMar 28 12:00 ET · Announcements
Summary of the 2024 Annual Report of Chengdu Olin Biotechnology Co., Ltd.
SZSIMar 28 12:00 ET · Announcements
Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 38% Share Price Surge Not Quite Adding Up
Simply Wall StMar 11 02:20 ET
Olin Biotech: Chengdu Olin Biotechnology Co., Ltd. 2024 Annual Results Express Announcement
SZSIFeb 27 11:00 ET · Announcements
Chengdu Olin Biotechnology Co., Ltd. 2024 Annual Results Express Announcement
SZSIFeb 27 11:00 ET · Announcements

Comments

Moomoo AI

Mar 4, 2024 14:15

Chengdu Olymvax Biopharmaceuticals' decent financial indicators and higher than average net income growth suggest potential for long-term stock price increase. The company's strategy of reinvesting all of its profits and the expected continuation of earnings expansion are seen as positive attributes.

Declining Stock and Decent Financials: Is The Market Wrong About Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319)?

Moomoo AI

Feb 1, 2024 09:40

Chengdu Olymvax Biopharmaceuticals' high P/S ratio may not be justified due to less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable. Also, there are 3 warning signs to consider.

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 31% But Getting In Cheap Is Still Unlikely

Moomoo AI

Dec 18, 2023 09:22

Despite weak revenue forecasts, the company's P/S ratio remains high, which could lead to significant investment risk if the high P/S ratio drops.

Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 28% Share Price Plunge Could Signal Some Risk

Moomoo AI

Oct 12, 2023 14:16

Chengdu Olymvax Biopharmaceuticals' ROE may be below industry average, but its steady net income growth could imply efficient management. With an expected earnings acceleration and all profits reinvested, the investment outlook seems positive.

Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

688319 Chengdu Olymvax Biopharmaceuticals Inc

Trade Overview

Capital Trend

News

Comments

Market Insights